- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Raising Awareness for Treating Adult Survivors of Childhood Cancers
Guidelines, such as those developed by the Children's Oncology Group, can prove a useful resource to monitor and/or treat adults who have previously been treated for a pediatric cancer.
General practitioners face a dilemma. In a recent survey (Ann Intern Med. 2014;160:11-17), most reported being unfamiliar with the guidelines and uncomfortable treating adult survivors of childhood cancer; however, they can expect to see more such patients each year as treatments for childhood cancer become increasingly successful.
Several measures can help internists when such patients come into their practice, according to Lisa Diller, MD, chief medical officer of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and founder and director of the David B. Perini Jr. Quality of Life Clinic.
"It's hard," Dr. Diller told Medscape Medical News. "The patient is worried about relapse, and sometimes relapse can present with very common symptoms, such as back pain." Internists can worry about missing an important development and overtest, or miss the red flags raised by the seeming pedestrian nature of some symptoms. Even then, not all back pain is a warning sign, she explained.
Read the article here: http://bit.ly/1yWhnjP
Source: Medscape
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
